Tags

Type your tag names separated by a space and hit enter

Reassessment of external insulin infusion pumps.

Abstract

Continuous subcutaneous insulin infusion (CSII) therapy using external infusion pumps provides an alternative to multiple daily injections (MDI) for insulin-dependent diabetics who require intensive insulin therapy. CSII allows for the delivery of regular insulin continuously at preset basal rates and at bolus doses, which can be varied in response to insulin needs of the patient. Intensive insulin therapy by CSII or MDI was administered to diabetics to improve control of their blood glucose levels and to assess its effects on the development of complications such as retinopathy and nephropathy. CSII appeared to be as effective as MDI in attaining near-normoglycemia and improving metabolic control in patients with insulin-dependent diabetes mellitus who required intensive insulin therapy. It was not clear, however, whether the improved control of the blood glucose levels resulted in the prevention or progression of the diabetic complications. The risks of having adverse effects, such as diabetic ketoacidosis or hypoglycemia, were higher with CSII as compared with MDI; both methods having higher risks of these complications in comparison to conventional insulin therapy. CSII may be beneficial for patients requiring intensive insulin therapy who may need greater lifestyle flexibility with regard to meal timing, work, and recreational scheduling.

Authors+Show Affiliations

DHHS, PHS, Agency for Health Care Policy and Research (AHCPR) Center for Research Dissemination and Liaison, Rockville, MD 20857.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2129578

Citation

Hotta, S S., and D Adams. "Reassessment of External Insulin Infusion Pumps." Health Technology Assessment Reports, 1990, pp. 1-9.
Hotta SS, Adams D. Reassessment of external insulin infusion pumps. Health Technol Assess Rep. 1990.
Hotta, S. S., & Adams, D. (1990). Reassessment of external insulin infusion pumps. Health Technology Assessment Reports, (9), 1-9.
Hotta SS, Adams D. Reassessment of External Insulin Infusion Pumps. Health Technol Assess Rep. 1990;(9)1-9. PubMed PMID: 2129578.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reassessment of external insulin infusion pumps. AU - Hotta,S S, AU - Adams,D, PY - 1990/1/1/pubmed PY - 1990/1/1/medline PY - 1990/1/1/entrez SP - 1 EP - 9 JF - Health technology assessment reports JO - Health Technol Assess Rep IS - 9 N2 - Continuous subcutaneous insulin infusion (CSII) therapy using external infusion pumps provides an alternative to multiple daily injections (MDI) for insulin-dependent diabetics who require intensive insulin therapy. CSII allows for the delivery of regular insulin continuously at preset basal rates and at bolus doses, which can be varied in response to insulin needs of the patient. Intensive insulin therapy by CSII or MDI was administered to diabetics to improve control of their blood glucose levels and to assess its effects on the development of complications such as retinopathy and nephropathy. CSII appeared to be as effective as MDI in attaining near-normoglycemia and improving metabolic control in patients with insulin-dependent diabetes mellitus who required intensive insulin therapy. It was not clear, however, whether the improved control of the blood glucose levels resulted in the prevention or progression of the diabetic complications. The risks of having adverse effects, such as diabetic ketoacidosis or hypoglycemia, were higher with CSII as compared with MDI; both methods having higher risks of these complications in comparison to conventional insulin therapy. CSII may be beneficial for patients requiring intensive insulin therapy who may need greater lifestyle flexibility with regard to meal timing, work, and recreational scheduling. SN - 8755-9765 UR - https://www.unboundmedicine.com/medline/citation/2129578/Reassessment_of_external_insulin_infusion_pumps_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.